← All trials
NCT05194072
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2022
- Primary completion
- Jun 30, 2025
- Completion date
- Jan 31, 2027
- First posted
- Jan 18, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 375
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seattle GeneticsLead sponsor
- Seattle GeneticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.